Picture Berlin Partner HealthCapital Bionnale 2019 Germany May 650x80px
Document › Details

IDT Biologika GmbH. (8/1/13). "Press Release: IDT Biologika GmbH Acquires Production Facility of Riemser Pharma GmbH and Animal Health Division at Greifswald-Isle of Riems Site". Dessau-Roslau & Greifswald-Isle of Riems.

Region Region Greifswald
  Country Germany
Organisations Organisation IDT Biologika (Riems) GmbH & CO. KG
  Group Klocke (Group)
  Organisation 2 Riemser Pharma GmbH
Products Product DRUGS, VETERINARY
  Product 2 vaccine
Index terms Index term Axa–Klocke: investment, 201308–201311 acquisition €na of Animal Health div of Riemser Pharma GmbH + production facility in Riems by IDT Biologika
  Index term 2 BBG/Braun Group–Axa: investment, 201208 acquisition of Riemser Arzneimittel AG from Braun family + minority shareolders incl TVM Capital
Persons Person Pfirmann, Ralf (Klocke 201308 CEO of IDT Bioligika GmbH)
  Person 2 Mehler, Michael (AXA 201208 CEO of Riemser Pharma before Actelion + Novartis)

Riemser Pharma GmbH and IDT Biologika GmbH contractually agreed on the acquisition of the remaining Animal Health Division and the production facility of Riemser Pharma GmbH in Greifswald-Isle of Riems by IDT Biologika (Riems) GmbH & Co. KG, a wholly-owned subsidiary of IDT Biologika GmbH. In the future, IDT Biologika will manufacture vaccines, mainly for veterinary medical applications, at its new subsidiary company in Riems. The purchase agreement has been signed, and the operational transfer is scheduled for 1 November 2013. Financial details of the agreement will not be disclosed.

IDT Biologika will use the manufacturing site in Riems as part of the production of its Business Unit Vaccines and under its responsibility. Research activities for animal health vaccines will also be based in Riems. Riemser Pharma GmbH will maintain the headquarters with its main corporate functions in Riems.

"As part of our corporate strategy, we want to promote sustained and consistently profitable growth. Our positive business development is based on globally leading products for the protection of human and animal health. The Riems site will enable IDT Biologika to achieve further growth in the vaccines segment", summarised the CEO of IDT Biologika, Dr. Ralf Pfirmann. "We are convinced that the integration of the Riems employees into IDT will enhance the knowledge and expertise of our workforce, and the production facilities in Riems will soon be contributing to the sales and productivity development of IDT as a whole. IDT is interested in a continuous input of innovation and, with the proximity to the Friedrich-Loeffler-Institute, we will now be able jointly to launch even more cutting edge projects in the animal health sector."

"The sale of the production in Riems and the remainder of our previous animal health business enables us to continue our development as an international specialty pharmaceutical company and to focus on growth in selected human medicine areas with high medical need", explains Dr. Michael Mehler, Chairman of the Board of Management of Riemser. "We are pleased to transfer the production to IDT Biologika and thereby contribute to another company of the healthcare industry becoming established in our region", adds Dr. Mehler.

About IDT Biologika

IDT Biologika is an innovative, privately-held company with more than 90 years of experience in researching, developing, manufacturing and marketing of biologics. The company focuses on three core areas - animal health, human vaccines, and pharmaceuticals: For veterinary markets, IDT Biologika manufactures and markets a comprehensive range of high-quality vaccines and other products for animal health. For vaccines, IDT Biologika offers development service and manufacturing facilities for clinical phase I to III as well as commercial supplies for leading edge viral and bacterial human vaccines, addressing health issues such as tuberculosis, AIDS, malaria and pox. For pharmaceutical markets, IDT Biologika specializes in the development and manufacture of sterile liquid drugs, providing fully-integrated service s ranging from formulation development and clinical manufacturing through to large-scale production, packaging and quality controI.

The company has experience in technically sophisticated projects, such as innovative biopharmaceuticals and lyophilized compounds, in EMA- and FDA-inspected facilities.

IDT Biologika is a member of the Klocke Group. With more than 1.500 employees at six locations worldwide the Klocke Group has been offering its customers a complete range of service s for contract manufacture and contract packaging, from development, production and filling through to the development of customised packaging methods and packing for more than 40 years. The Group also has extensive experience in contract manufacturing of solid dosage forms and cytostatics.

About RIEMSER Pharma GmbH

RIEMSER Pharma GmbH, headquartered in Greifswald, Germany, is a midsize specialty pharmaceutical company which markets its products in Germany and worldwide. RIEMSER focuses principally on prescription-only human pharmaceuticals in selected therapeutic markets with high medical need, in particular Oncology, Anti-infectives and Dermatology.

Record changed: 2017-04-02


Picture [LSE] – The Business Web Portal 650x65px

More documents for Klocke (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top